Accuray Accelerates Transformation Efforts with Appointment of Experienced Executive Leaders to Drive Performance and Growth
Accuray (NASDAQ: ARAY) announced a leadership and board overhaul to accelerate a company-wide transformation, effective October 20, 2025. Steve La Neve was appointed CEO and Suzanne Winter will retire and remain an advisor through November. Steven F. Mayer was named Transformation Board Sponsor and Chan W. Galbato was nominated to the board.
The company provided preliminary fiscal 2026 Q1 figures: total revenues of $92.5–$94.0 million and adjusted EBITDA of approximately ($4) million. Management said service revenues exceeded plan while product revenues missed expectations in EIMEA and China. The Board targets a high single‑digit adjusted EBITDA margin run‑rate within 12 months and double‑digit margins over the medium to long term.
Accuray (NASDAQ: ARAY) ha annunciato una ristrutturazione della leadership e del consiglio per accelerare una trasformazione aziendale, effettiva 20 ottobre 2025. Steve La Neve è stato nominato CEO e Suzanne Winter si ritirerà ma rimarrà come consulente fino a novembre. Steven F. Mayer è stato nominato Transformation Board Sponsor e Chan W. Galbato è stato proposto per il consiglio.
L'azienda ha fornito dati preliminari sul primo trimestre dell'esercizio 2026: ricavi totali tra 92,5–94,0 milioni di dollari e EBITDA rettificato di circa (4) milioni. Il management ha detto che i ricavi di servizi hanno superato le previsioni mentre i ricavi di prodotto hanno mancato le aspettative in EIMEA e in Cina. Il Consiglio mira a una margine EBITDA rettificato a una cifra elevata a regime entro 12 mesi e a margini a due cifre nel medio-lungo termine.
Accuray (NASDAQ: ARAY) anunció una reorganización de liderazgo y de la junta para acelerar una transformación a nivel de la empresa, con efecto a partir de 20 de octubre de 2025. Steve La Neve fue nombrado CEO y Suzanne Winter se retirará y permanecerá como asesora hasta noviembre. Steven F. Mayer fue designado como Transformation Board Sponsor y Chan W. Galbato fue propuesto para la junta.
La compañía proporcionó las cifras preliminares del primer trimestre fiscal 2026: ingresos totales de $92.5–$94.0 millones y EBITDA ajustado de aproximadamente ($4) millones. La dirección dijo que los ingresos por servicios superaron el plan, mientras que los ingresos por productos no alcanzaron las expectativas en EIMEA y China. La Junta apunta a una margen EBITDA ajustado de un solo dígito alto a ritmo dentro de 12 meses y márgenes de dos dígitos a medio y largo plazo.
Accuray (NASDAQ: ARAY)은 회사 전반의 변화를 가속화하기 위한 리더십과 이사회 개편을 발표했으며, 발효는 2025년 10월 20일입니다. Steve La Neve가 CEO로 임명되었고 Suzanne Winter은 은퇴하고 11월까지 자문으로 남습니다. Steven F. Mayer가 Transformation Board Sponsor로 지명되었고 Chan W. Galbato가 이사회에 지명되었습니다.
회사는 2026 회계연도 1분기 예비 실적을 제공했습니다: 총 매출 $92.5–$94.0 백만과 조정 EBITDA 약 ($4) 백만입니다. 경영진은 서비스 매출이 계획을 상회했다고 말했지만 EIMEA와 중국에서 제품 매출은 기대를 밑돌았습니다. 이사회는 12개월 이내에 조정 EBITDA 마진의 고단일자리 런레이트를 목표로 하고 중장기적으로 두 자릿수 마진을 목표로 하고 있습니다.
Accuray (NASDAQ: ARAY) a annoncé une refonte de la direction et du conseil d'administration afin d'accélérer une transformation à l'échelle de l'entreprise, effective le 20 octobre 2025. Steve La Neve a été nommé PDG et Suzanne Winter prendra sa retraite et restera conseillère jusqu'en novembre. Steven F. Mayer a été nommé sponsor du Transformation Board et Chan W. Galbato a été nominé au conseil d'administration.
La société a donné des chiffres préliminaires pour le premier trimestre fiscal 2026: revenus totaux de $92,5–$94,0 millions et EBITDA ajusté d'environ (4) millions. La direction a indiqué que les revenus de service ont dépassé le plan, tandis que les revenus de produits n'ont pas atteint les attentes en EIMEA et en Chine. Le Conseil vise une marge EBITDA ajustée à un chiffre élevé en rythme sur 12 mois et des marges à deux chiffres à moyen et long terme.
Accuray (NASDAQ: ARAY) kündigte eine Führungs- und Vorstandsreform an, um eine unternehmensweite Transformation zu beschleunigen, wirksam ab 20. Oktober 2025. Steve La Neve wurde zum CEO ernannt und Suzanne Winter wird in den Ruhestand treten und bis November als Beraterin bleiben. Steven F. Mayer wurde zum Transformation Board Sponsor ernannt und Chan W. Galbato wurde für den Vorstand nominiert.
Das Unternehmen legte vorläufige Zahlen für das erste Quartal des Geschäftsjahres 2026 vor: Gesamtumsatz von $92,5–$94,0 Millionen und bereinigtes EBITDA von etwa ($4) Millionen. Das Management sagte, dass die Serviceerlöse den Plan übertroffen, während die Produktumsätze in EIMEA und China hinter den Erwartungen blieben. Der Vorstand strebt innerhalb von 12 Monaten eine laufende EBITDA-Marge im hohen einstelligen Bereich und langfristig zweistellige Margen an.
Accuray (NASDAQ: ARAY) أعلنت عن إعادة هيكلة للقيادة والمجلس من أجل تسريع التحول على مستوى الشركة، مع سريانها في 20 تشرين الأول/أكتوبر 2025. تم تعيين ستيف لا نيڤ رئيساً تنفيذياً وستتقاعد Suzanne Winter وتظل مستشارة حتى نوفمبر. تم تسمية ستيفن ف. ماير كراعي مجلس التحول وتم ترشيح تشان و. غالباتو للمجلس.
قدمت الشركة أرقاماً أولية للربع الأول من السنة المالية 2026: إيرادات إجمالية بين $92.5–$94.0 مليون وربح EBITDA معدّل يقارب ($4) مليون. أشارت الإدارة إلى أن إيرادات الخدمات فاقت الخطة بينما لم تحقق إيرادات المنتجات المتوقع في EIMEA والصين. يسعى المجلس إلى معدل EBITDA المعدّل في نطاق عالٍ من العشر الأرقام خلال 12 شهراً وعلى المدى المتوسط والطويل إلى هوامش ذات أرقام مزدوجة.
Accuray (NASDAQ: ARAY) 宣布进行领导层和董事会的整合改革，以加速全公司范围的转型，自2025年10月20日起生效。 Steve La Neve 被任命为首席执行官，Suzanne Winter 将退休并在11月前担任顾问。 Steven F. Mayer 被任命为 Transformation Board Sponsor，Chan W. Galbato 被提名进入董事会。
公司提供了2026财年第一季度的初步数据：总收入为$92.5–$94.0 百万美元，经调整后的 EBITDA 约为($4) 百万美元。管理层表示，服务收入超出计划，而 EIMEA 与中国的产品收入未达到预期。董事会在12个月内的目标是实现高个位数的经调整 EBITDA 运行率，中长期实现两位数利润率。
- Experienced CEO appointment effective Oct 20, 2025
- Preliminary Q1 revenues of $92.5–$94.0M
- Service revenues reported ahead of plan
- Target: high single‑digit adjusted EBITDA margin within 12 months
- Preliminary adjusted EBITDA of approximately ($4)M
- Product revenues below expectations in EIMEA and China
- Preliminary results may change materially pending final audit
Insights
Board installs experienced operators to accelerate a company-wide transformation and governance oversight.
The Board appointed Steve La Neve as CEO effective
Execution depends on disciplined implementation of the transformation initiatives the company says will occur mostly within the current fiscal year, and on the Board/management alignment overseen by the new sponsor. Watch the company’s detailed transformation milestones, quarterly progress updates, and any material adjustments to the plan over the next
Preliminary Q1 fiscal 2026 figures show mixed top-line results and a small adjusted EBITDA loss.
Preliminary revenues for fiscal Q1 are reported at
Key near-term monitors include the finalized Q1 results expected with the release of summary information on
Industry Veteran Steve La Neve Named Chief Executive Officer
Suzanne Winter to Retire as President and CEO
Company Appoints Steven F. Mayer as Transformation Board Sponsor
Chan W. Galbato Nominated to Board of Directors
As part of these actions, the Board has appointed Steve La Neve as Chief Executive Officer, effective today, October 20, 2025. He succeeds Suzanne Winter, who will retire after six years of service and remain in an advisory role through the end of November to ensure a seamless transition.
"With Accuray's transformation plan well underway, these leadership appointments are proactive steps to add momentum and position the company for long-term success," said Joe Whitters, Chairman of the Board. "Steve's proven record of operational excellence and value creation at leading med-tech companies makes him exceptionally well suited to guide Accuray through its next phase of growth. The Board is committed to disciplined execution directed at expanding margins, enhancing competitiveness, and building a more agile, customer-focused organization while continuing the innovation that defines Accuray. We thank Suzanne for her leadership and lasting contributions in advancing our technology and strengthening our global presence."
Mr. La Neve brings more than 40 years of international medical-technology experience with a track record of driving margin expansion and revenue growth. He previously served as President of the Trauma and Joint Reconstruction business unit of Globus Medical Inc. and President of Globus Medical Japan K.K., Chief Executive Officer and Board Member of Bone Biologics Corporation, Global President of Becton Dickinson Preanalytical Systems, and as Global Sector President for Medtronic's Spine and Biologics Division.
"Accuray's mission to deliver the curative power of radiation therapy to patients around the world is both inspiring and urgent," said Mr. La Neve. "Accuray is one of just a few companies operating at the intersection of technical sophistication and human impact. The company has a robust installed base and is rapidly increasing its presence across several of the fastest growing markets globally. And our solutions continue to resonate, with order backlog continuing to be strong. I'm excited to work with the talented team at Accuray to build on this promise and foster a performance-driven culture that pairs innovation with execution, strengthens operational discipline, and drives sustainable, profitable growth. We will execute our transformation plan with clarity, confidence, and purpose to enhance our competitiveness and create long-term value for the patients, providers, and shareholders we serve."
Board and Governance Updates
To support the execution of the company's transformation and growth strategy, the Board announced two additional leadership changes.
Steven F. Mayer, who joined the Board in June 2025, has been appointed Transformation Board Sponsor and will partner closely with incoming CEO Steve La Neve and the management team to oversee execution of the company's organizational, strategic and operational initiatives. Mr. Mayer brings extensive experience leading complex corporate transformations, having served nearly two decades at Cerberus Capital Management as Senior Managing Director, Co-Head of Global Private Equity, and Chairman of the Investment Committee. Most recently, after retiring from Cerberus, he served as Executive Chairman of global healthcare company Grifols, S.A., where he designed and led a company-wide transformation that realigned the organization and delivered more than
"I'm excited to partner with Steve La Neve and the Board to accelerate Accuray's transformation," added Mr. Mayer. "We are developing a clear plan that we've been investing behind, with strong leadership and a focused team ready to execute. We are acting decisively to align with strategic objectives, strengthen operations and deliver meaningful performance gains. We expect to reach a high single-digit adjusted EBITDA margin run-rate within twelve months and to expand that margin to double digits over the medium to long term. With its powerful combination of technology, talent, and purpose, Accuray is well positioned to compete more effectively and deliver sustained, profitable results."
In addition, Chan W. Galbato has been nominated to the Accuray Board of Directors. Mr. Galbato brings more than 30 years of operational and strategic leadership experience across global enterprises. He currently serves as Senior Advisor to Barington Capital Group and Alvarez & Marsal Holdings and has held senior executive roles including Co-Chair of Albertsons Companies, CEO of Cerberus Operations and Advisory Company, and leadership positions at Invensys, The Home Depot, and GE. A seasoned board member, he has served on numerous public and private company boards, including as chair of several publicly traded organizations.
FTI Consulting continues to advise the company on its operational execution and transformation strategy. TCW, the company's strategic lending partner, expressed strong support for the transformation plan and the accompanying leadership changes.
Fiscal 2026 First Quarter Financial Results
Accuray expects to release summary financial information for its fiscal 2026 first quarter on November 5. In connection with today's announcement, the company is providing select preliminary information concerning its first quarter financial results. In its fiscal 2026 first quarter, service revenues were ahead of plan but product revenues were below expectations in EIMEA and
The foregoing preliminary unaudited financial information for the fiscal 2026 first quarter is derived from preliminary internal financial reports. The company has not yet finalized its complete results of operations for the quarter ended September 30, 2025. The company may identify items that would require it to make adjustments, some of which could be material, to the preliminary unaudited financial information set forth in this press release.
About Accuray
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in
Forward-Looking Statements
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to the company's future results of operations, including expectations regarding: service and product revenue, total revenue and adjusted EBITDA; adjusted EBITDA margin run rates; the company's ability to execute upon and realize the benefits of its transformation and growth strategy; the company's transformation plan initiatives, including timing and expected benefits; the company's leadership changes; the company's ability to achieve its short and long-term goals; and expectations related to the markets and regions in which the company operates. These forward-looking statements involve risks and uncertainties. If any of these risk or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results express or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the ability of the company to execute upon its transformation plan; the effect of the global macroeconomic environment on the operations of the company and those of its customers and suppliers; disruptions to the company's supply chain, including increased logistics costs; the company's ability to achieve widespread market acceptance of its products; substantial outstanding indebtedness and its ability to maintain compliance with financial covenants related to its debt; the effect of enhanced international tariffs on the company; the company's ability to realize the expected benefits of the
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Investor Relations Contact
Aman Patel, CFA
Investor Relations, ICR Healthcare
aman.patel@ICRHealthcare.com
Media Contact
Beth Kaplan
Public Relations Director, Accuray
bkaplan@accuray.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/accuray-accelerates-transformation-efforts-with-appointment-of-experienced-executive-leaders-to-drive-performance-and-growth-302588796.html
SOURCE Accuray Incorporated
FAQ
Who is the new CEO of Accuray (ARAY) and when did they start?
What preliminary fiscal 2026 Q1 revenue did Accuray (ARAY) report on Oct 20, 2025?
What was Accuray's (ARAY) preliminary adjusted EBITDA for fiscal 2026 Q1?
What caused the revenue shortfall in Accuray's (ARAY) fiscal Q1 results?
What margin targets did Accuray (ARAY) announce with its transformation plan?
Will Accuray's (ARAY) preliminary Q1 results change after final reporting?
